Skip to main content

Table 1 Gonorrhoea patient characteristics in 2016 and 2019

From: Significant increase in azithromycin “resistance” and susceptibility to ceftriaxone and cefixime in Neisseria gonorrhoeae isolates in 26 European countries, 2019

 

2016

2019

N (%)

N (%)

Total number of isolatesa

2559

3239

Sex

 Male

2158 (84.7)

2676 (84.2)

 Female

391 (15.3)

502 (15.8)

 Not reported

10

61

Age (years)

 < 25

668 (26.5)

883 (28.4)

 ≥ 25

1854 (73.5)

2223 (71.6)

 Not reported

37

133

Sexual orientation and sex

 Females

391 (24.4)

501 (25.6)

 Heterosexual males

539 (33.6)

545 (27.9)*

 Men who have sex with men

672 (41.9)

908 (46.5)*

 Not reported

957

1285

Site of infection

 Urogenital

1745 (75.1)

2076 (71.5)*

 Pharyngeal

153 (6.6)

262 (9.0)*

 Anorectal

329 (14.2)

475 (16.4)*

 Other

97 (4.2)

91 (3.1)*

 Not reported

235

335

Previous gonorrhoea

 Yes

163 (16.7)

228 (23.2)*

 No

814 (83.3)

753 (76.8)*

 Not reported

1582

2258

Concurrent sexually transmitted infection (STI)

 Concurrent chlamydia infection

181 (23.5)

228 (21.2)

 Concurrent other STI (not HIV)

51 (6.6)

83 (7.7)

 No concurrent STI

539 (69.9)

764 (71.1)

 Not reported

1788

2164

HIV status

 Positive

143 (15.8)

139 (13.1)

 Negative

760 (84.2)

926 (86.9)

 Not reported

1656

2174

  1. aTotal number of isolates includes a maximum of 200 isolates per country. Three countries exceeded the 200 isolate limit in 2016; The Netherlands, Spain and the UK. In 2019 seven countries exceeded 200 isolates; Austria, Finland, France, The Netherlands, Norway, Spain and the UK
  2. *Bold letters indicate significant difference between 2016 and 2019 by Z-test (p < 0.05)